Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Most study participants achieved viral suppression with minimal changes in kidney function or bone density.
Gilead Sciences? pair of investigatory hepatitis C virus therapies led to a 100 percent cure rate among a small cohort of patients.
Bristol-Myers Squibb (BMS) has officially halted development of BMS-986094, a once-promising nucleotide polymerase (NS5B) inhibitor, due...
Despite rapid reductions in hepatitis C virus (HCV) levels in 10 previously treated null responders with genotype 1 HCV, only one person had a...
Princeton, New Jersey-based Pharmasset is putting its lead experimental hepatitis C nucleotide inhibitor to the test in three late-stage...
Antiviral drug developer Pharmasset is gearing up to present â€œstartling resultsâ€ from its early clinical trial of two nucleotide a...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.